Abbott Laboratories’ ABT growth in the fourth quarter of 2024 can be attributed to strong improvement in global Core Laboratory Diagnostics sales, led by continued strong demand for its portfolio of ...

Strong growth in the Libre CGM segment, with sales surpassing $1.6 billion. Abbott is targeting high single-digit top-line growth in 2025. Abbott Laboratories demonstrated solid performance in Q3 ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS increase.

In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As ...

Abbott Laboratories is a well-diversified health care company, with four distinct units: medical devices, diagnostics, nutrition and ...

Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management.

Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), Abbott Laboratories ... Lingo and Libre Rio CGM devices are on a great trajectory.

The upbeat results demonstrate DexCom’s position as a key player in the continuous glucose monitoring (CGM ... has gained 8.5% while its peer Abbott Laboratories ABT inched up 0.3%.DXCM has ...